Vistagen therapeutics reports fiscal year 2022 first quarter financial results and provides corporate update

Palisade phase 3 program to evaluate ph94b for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (sad) progressing on plan
VTGN Ratings Summary
VTGN Quant Ranking